Genmab Announced Sunday At ESMO, Updated Phase 2 Petosemtamab Plus Chemotherapy Data Showing 75% First-Line, 67% Second-Line Response Rates In Metastatic Colorectal Cancer
Share
Why It Matters
Genmab shared new test results for a cancer medicine. The drug helped many patients, which is good news for the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.